Biotech Startups in Massachusetts

Alzheon, Inc. is a biotechnology company dedicated to developing innovative treatments for Alzheimer's disease. The company focuses on creating therapeutics that aim to slow or halt the progression of Alzheimer's and potentially prevent the onset of clinical symptoms.

Carna Biosciences, Inc. is a biotechnology company dedicated to drug discovery and the development of small molecule drugs. The company aims to address unmet medical needs by offering innovative therapeutic solutions in areas where current treatments are either inadequate or non-existent.

Founded 2021

Consano Bio is an early-stage biotechnology startup founded in 2022 and headquartered in Des Moines, Iowa. The company focuses on developing first-in-category biologic therapeutics to treat painful and debilitating orthopedic conditions. Its core strategy is to target the underlying drivers of disease rather than merely addressing symptoms.

Founded 2022

DeepkinetiX Inc. is a pioneering company dedicated to revolutionizing the drug development landscape through the innovative application of artificial intelligence and computational modeling techniques. By employing advanced technologies, they strive to optimize pharmacokinetic and pharmacodynamic processes, fostering speed and precision in drug analysis.

Founded 2024

Ernexa Therapeutics Inc. is a biotechnology company focused on developing cell therapy solutions for advanced cancer and autoimmune diseases. They use induced pluripotent stem cells (iPSCs) to create induced mesenchymal stem cells (iMSCs) with unique targeting capabilities, enabling the creation of scalable, off-the-shelf therapies. This method eliminates the need for patient-specific solutions.

Lapix Therapeutics Inc. is a clinical-stage biopharmaceutical company based in Cambridge, MA, dedicated to developing innovative oral therapeutics that restore immune system function for patients with autoimmune diseases. Through a patient-centric approach, Lapix Therapeutics is pioneering treatments that enhance the body's natural immune tolerance.

Lyra Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing groundbreaking therapies specifically for chronic rhinosinusitis (CRS), a prevalent inflammatory condition affecting the nasal passages and sinuses. By leveraging innovative technologies, Lyra aims to provide effective solutions for CRS patients who often endure ineffective treatments and potentially invasive surgeries.

Founded 2024

Medici Therapeutics, Inc. is a biotechnology company focused on developing advanced cancer treatments within the immunotherapy sector. The company's primary focus is on advancing tumor-infiltrating lymphocyte (TIL) therapies by leveraging novel insights into cancer immunology, particularly how cancer cells evade immune responses.

Founded 2021

Neutrolis Inc. is a clinical-stage biotechnology firm that specializes in developing innovative therapies aimed at autoimmune and inflammatory diseases. The company's unique approach focuses on targeting Neutrophil Extracellular Traps (NETs), which are implicated in tissue damage and chronic inflammation associated with several immune-mediated disorders, such as lupus and dry eye disease, as well as severe complications from conditions like COVID-19.

Newleos Therapeutics, Inc. is a pioneering clinical-stage neuroscience company focused on the innovation of therapies for neuropsychiatric disorders. With a commitment to addressing the pressing unmet needs in mental health, Newleos is dedicated to developing effective tools for anxiety and substance use disorders, impacting millions across the United States.

Founded 2024

Odyssey Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies for autoimmune and inflammatory diseases. The company's strategy involves targeting upstream signaling nodes in the innate immune system to prevent pathological inflammation before it starts, aiming to induce long-lasting remission for patients.

Founded 2021

PhAST Corp. is a biotechnology company specializing in the transformation of infectious disease diagnostics through innovative rapid diagnostic technology. With a focus on minimizing turnaround times for pathogen detection and testing, PhAST Corp. aims to enhance patient care by enabling timely treatment decisions.

Phio Pharmaceuticals Corp. is a biotechnology company specializing in the development of groundbreaking therapeutics, particularly in the field of immuno-oncology. Utilizing their proprietary technology platform, they focus on addressing unmet medical needs to potentially enhance cancer treatment outcomes.

seqWell Inc. is a biotechnology company dedicated to advancing the efficiency and accuracy of DNA/RNA library preparation workflows for next-generation sequencing (NGS). By pioneering innovative solutions, seqWell streamlines complex processes, making genetic testing more accessible and reliable for laboratories worldwide.

Syntis Bio, Inc. is a pioneering biotechnology company focused on transforming oral therapeutics through innovative solutions targeting the small intestine. By leveraging its proprietary SYNT™ platform, the company enhances the absorption and effectiveness of treatments for prevalent and challenging conditions such as obesity, diabetes, and rare diseases.

Founded 2022

Tectonic Therapeutic, Inc. is a pioneering biotechnology company based in Watertown, Massachusetts, dedicated to the discovery and development of advanced therapeutic proteins and antibodies. The company primarily focuses on harnessing the potential of G-Protein Coupled Receptors (GPCRs), which are integral to numerous biological processes and disease pathways.

Third Pole, Inc. is an innovative biotechnology company dedicated to developing and delivering essential life-sustaining therapies for cardiopulmonary conditions. The company specializes in creating portable, tankless inhaled nitric oxide (iNO) delivery systems to enhance accessibility and patient care.

Vaxess Technologies, Inc. is a pioneering life sciences company focused on the development of innovative vaccine and therapeutic delivery technologies. Their flagship product, the MIMIX™ platform, is a cutting-edge transdermal patch system that aims to make vaccines and therapeutics more effective and accessible, particularly in challenging environments.